A multicentric phase 2 study was conducted to determine the efficiency and the tolerance of imatinib mesylate in children with chronic myelogenous leukemia (CML) in advanced phase of the disease ...

Between December 1999 and June 2001, we treated 133 patients with chronic myeloid leukemia with imatinib mesylate according to Novartis Pharma protocols. 1,2 Among these 133 patients, 5 men and 4 ...

In a recent cross-sectional study, Berman et al. found that some patients who were treated with imatinib mesylate had hypophosphatemia, with low-normal serum calcium levels, elevated levels of ...

Leukemia - Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis Skip to main content Thank you for visiting nature.com.

The selective BCR-ABL1 kinase inhibitor imatinib mesylate (Gleevec) has been found to be safe and effective following almost 11 years of follow-up in patients with chronic myeloid leukemia.

As stated in the FDA approval letter, Sun Pharma’s Imatinib Mesylate ANDA contains a statement under section 505(j)(2)(A)(viii) of the FD&C Act representing that its application did not seek ...

IMATINIB MESYLATE - INDICATIONS AND USAGE Imatinib Mesylate is a kinase inhibitor indicated for the treatment of: • Newly diagnosed adult and pediatric patients with Philadelphia chromosome ...

Patients with GBM at any recurrence received imatinib mesylate plus hydroxyurea (500 mg twice a day) orally on a continuous, daily schedule. The imatinib mesylate dose was 500 mg twice a day for ...